BioAge Labs (NASDAQ:BIOA) Trading Up 5.5% – Should You Buy?

BioAge Labs, Inc. (NASDAQ:BIOA)’s stock price rose 5.5% on Friday . The stock traded as high as $23.09 and last traded at $23.3710. Approximately 51,852 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 609,561 shares. The stock had previously closed at $22.16.

Analyst Upgrades and Downgrades

Several research analysts have commented on BIOA shares. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Needham & Company LLC started coverage on shares of BioAge Labs in a report on Friday, March 27th. They set a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Roth Capital initiated coverage on shares of BioAge Labs in a research note on Wednesday, May 27th. They issued a “buy” rating and a $36.00 price objective for the company. Finally, BTIG Research started coverage on shares of BioAge Labs in a research report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 target price on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioAge Labs currently has an average rating of “Moderate Buy” and an average price target of $43.50.

BioAge Labs Price Performance

The company has a fifty day moving average price of $19.88 and a two-hundred day moving average price of $19.01. The company has a market capitalization of $1.01 billion, a P/E ratio of -9.50 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The business had revenue of $2.77 million during the quarter. As a group, sell-side analysts forecast that BioAge Labs, Inc. will post -2.68 earnings per share for the current year.

Institutional Trading of BioAge Labs

Several institutional investors have recently modified their holdings of the business. Nano Cap New Millennium Growth Fund L P bought a new position in shares of BioAge Labs during the fourth quarter worth about $1,058,000. Y Intercept Hong Kong Ltd acquired a new position in shares of BioAge Labs in the first quarter worth approximately $3,521,000. Stempoint Capital LP bought a new stake in BioAge Labs in the first quarter valued at approximately $5,923,000. Janus Henderson Group PLC increased its position in BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after purchasing an additional 1,685,063 shares during the period. Finally, Octagon Capital Advisors LP increased its position in BioAge Labs by 9.4% during the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after purchasing an additional 150,000 shares during the period.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.